Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children Patients with core binding factor acute myeloid leukemia (CBF-AML) with translocation (8;21)(q22;q22) [t(8;21)] and inversion of chromosome 16(p13.1q22), or its variant t(16;16) (p13.1;q22) [inv(16)], generally have favorable outcomes, as the probabilities of event-free survival (pEFS) and overall survival (pOS) were around 80% and 90%, respectively, in recent clinical trials of pediatric AML. [1] [2] [3] It is well recognized that intensive post remission chemotherapy with high-dose cytarabine (HDCA) has contributed to the improved survival of CBF-AML. 4, 5 Although there is evidence that high doses of anthracyclines-another key component of AML chemotherapy-improves the outcomes in children and adults with AML, 6, 7 its effects in CBF-AML are not well established, unlike those of HDCA. Moreover, higher doses of anthracyclines are associated with increased risk of late cardiotoxicity, which could occur at a lower cumulative dose (for example, 4300 mg/m 2 ) in children than in adults. 8 Therefore, it needs to be evaluated whether intensive use of HDCA could compensate for a reduction in the other treatment components, especially the cumulative anthracycline dose, by maintaining high pEFS and pOS and reducing the risk of late complications such as anthracycline-induced cardiotoxicity in particular.
Following the excellent outcomes of the AML99 study line conducted by the Japanese Childhood AML Cooperative Study Group, 2 a nationwide multicenter study (termed the AML-05 study) was conducted by a new national study group established in 2003, the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG), to optimize risk-stratified therapies for childhood AML. This trial is registered with UMIN Clinical Trials Registry (UMIN-CTR, URL: http://www.umin.ac.jp/ctr/index.htm), number UMIN000000511. The main objective for the low-risk (LR) group, which included most of the patients with CBF-AML, was to evaluate the efficacy and safety of a chemotherapy regimen comprising a reduced cumulative dose of anthracyclines and etoposide. Between November 2006 and December 2010, 485 consecutive patients aged o18 years with suspected AML diagnosed at 118 centers and hospitals in Japan were registered in AML-05. Patients with acute promyelocytic leukemia, Down syndrome, secondary AML, myeloid/natural killer cell leukemia and myeloid sarcoma were not eligible. AML was diagnosed using the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues (3rd edition). 9 Among the 443 eligible patients, 122 (27.5%) presented with t(8;21) and 32 (7.2%) with inv(16). Their data were compared with historical controls consisting of 89 CBF-AML children in the previous AML99 study. Written informed consent, provided according to the Declaration of Helsinki, was obtained from the guardians of the patients. All aspects of the study were approved by the Institutional Review Boards at all the participating institutions. The therapeutic regimens used in the AML-05 and AML99 studies are presented in Figure 1 . Several changes were introduced in AML-05
Accepted article preview online 16 May 2013; advance online publication, 4 June 2013 Letters to the Editor compared with AML99. First, the initial induction course was unified to the ECM (consisted of etoposide, cytarabine and mitoxantrone, with triple intrathecal chemotherapy). Second, the risk groups were redefined as follows: all of the CBF-AML patients with good initial responses after the initial induction course were included in the LR group, without considering the patient's age and white blood cell (WBC) count, while patients with Fms-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) were included in the high-risk (HR) group. We also reduced the total number of chemotherapy courses from six to five. Finally, the indication for allogeneic hematopoietic stem cell transplantation (HSCT) was limited to the HR group. Therefore, most of the patients with CBF-AML (87.6% (135/154)) were included in the LR group and received five courses of intensive chemotherapy, of which four included HDCA, but the cumulative anthracycline dose was limited to 225 mg/m 2 daunorubicin-equivalents (the cumulative anthracycline dose was calculated relative to the amount of daunorubicin using a conversion rate of 5:1 for daunorubicin to mitoxantrone/idarubicin). A small subset of patients with HR CBF-AML (5.1% (8/154)), those with residual leukemia in any site after the initial induction course or those with FLT3-ITD, received HSCT at the first remission (1CR).
The characteristics of patients at diagnosis in the AML-05 and AML99 studies are reported in Table 1 . Sex, age and WBC count were comparable in both studies, but the distribution of FrenchAmerican-British classification categories differed. This is because the patients were diagnosed according to the WHO classification (3rd edition) in AML-05, which included patients with low bone marrow blast percentages of 20-30% who are classified as having refractory anemia with excess blasts in transformation (RAEB-T). Additionally, while FLT3-ITD status was prospectively examined in all patients in AML-05, it was examined retrospectively in approximately 60% of patients in AML99, although the difference was not significant.
Induction responses in children with CBF-AML were not significantly different between AML-05 and AML99. Among the 147 CBF-AML patients who achieved 1CR in AML-05, 135 patients were assigned to the LR group, while the other 8 patients were assigned to the HR group. Four patients with CBF-AML discontinued the study because of incorrect risk assignment in three and the guardian's decision in one. Among 87 CBF-AML patients who achieved 1CR in the AML99 study, 77 were assigned to the LR group, 7 to the intermediate-risk group and 3 to the HR group.
The 3-year pEFS, pOS and cumulative incidence of relapse (CIR) for all CBF-AML, t(8;21), inv(16), and CBF-AML without unfavorable factors (t(8;21) and WBC 450 000/ml, RAEB-T and FLT3-ITD) in AML-05 and AML99 are reported in Table 1 , and TIT on day 1. Ind-1, induction course 1; Ind-2, induction course 2; HSCT, allogeneic HSCT; MSD, matched sibling donor. *The cumulative anthracycline dose was calculated relative to the amount of daunorubicin using a conversion rate of 5:1 for daunorubicin to mitoxantrone/idarubicin.
(AML-05 vs AML99), age at initial diagnosis (X10 vs o10 years), sex (female vs male), WBC count at initial diagnosis (X50 000/ml vs o50 000/ml), and cytogenetics [inv(16) vs t(8;21)], were evaluated by univariate and multivariate analyses (patients receiving HSCT at 1CR were excluded). In Cox regression analysis, the adjusted hazard ratio for pEFS was significantly worse for patients treated in AML-05 than in patients treated in AML99 (hazard ratio, 2.088 (95% CI, 1.125-3.875); P ¼ 0.020), and was significantly better in patients aged X10 years at diagnosis compared with those aged o10 years at diagnosis (hazard ratio, 0.494 (95% CI, 0.271-0.899); P ¼ 0.021).
Thus, our attempt to reduce the cumulative dose of anthracyclines to o300 mg/m 2 for CBF-AML patients in AML-05, while maintaining the treatment intensity by using intensive HDAC in 4/5 treatment courses, resulted in the decrease of pEFS by B10% because of the higher CIR. Interestingly, this effect was prominent in patients aged o10 years at diagnosis, as the pEFS in children aged o10 years vs X10 years was 57.4 vs 82.6% in AML-05, while it was 82.0 vs 82.0% in AML99. Of course, it is not only the cumulative dose of anthracycline, but also the number of treatment courses and the cumulative dose of etoposide that were changed in AML-05 relative to those in AML99 (Figure 1) . However, high pEFS and pOS for CBF-AML were achieved with four to five treatment courses and a similar dose of etoposide in other studies 1, 3, 10 In addition, decrease in pEFS was not observed for non CBF-AML cases in AML-05 with similar changes in number of treatment courses and cumulative etoposide dose, while cumulative anthracycline dose was not changed from AML99 (to be reported in detail in a separate manuscript). Considering these facts, it is likely that the reduced cumulative anthracycline dose was responsible for the higher CIR in the current study than in AML99. Despite higher CIR among CBF-AML patients in AML-05, pOS was identical to that in AML99. However, the overall transplantation rate was higher in AML-05 than in AML99 (33% (51/154) vs 19% (17/89)), because most of the patients who experienced relapse underwent HSCT as second-line treatment, which is unlikely to be accepted by patients with CBF-AML. Therefore, we reintroduced the AML99-based post remission chemotherapeutic regimen for CBF-AML patients included in our subsequent study, AML-12. Nevertheless, the finding that nearly 70% of the CBF-AML patients were cured with very low doses of anthracyclines suggests that other underlying biological factors, such as KIT mutations, 11 should be identified for future stratification of CBF-AML in children.
In conclusion, the results of this study indicate that caution is needed when reducing the cumulative anthracycline dose to o300 mg/m 2 as part of conventional combination chemotherapy for treating CBF-AML in children. Several novel agents, including gemtuzumab ozogamicin, had clinical benefits for CBF-AML patients as part of induction chemotherapy. 12, 13 The introduction of such agents into combination chemotherapy might be required before considering further reduction of the anthracycline dose. Abbreviations: CBF-AML, core binding factor acute myeloid leukemia; CIR, cumulative incidence of relapse; CR, complete remission; FAB, FrenchAmerican-British; FLT3-ITD, Fms-like tyrosine kinase 3 internal tandem duplications; ND, not determined; NE, not evaluated; pEFS, probability of event-free survival; pOS, probability of overall survival; RAEB-T, refractory anemia with excess blasts in transformation; s.e., standard error; WBC, white blood cell.
Letters to the Editor
Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children Hispanic children have a 10-30% greater incidence rate of ALL than non-Hispanic whites, and nearly double the rate observed in African-Americans. 1 Ethnic differences in ALL incidence may be explained by population-level differences in the frequency of genetic risk factors, including those first discovered in genomewide association studies of European-ancestry populations. [2] [3] [4] [5] As Hispanics are an admixed population with European, African and Native American ancestry, differences in ALL incidence observed in Hispanics may be attributable to genetic risk factors associated with Native American ancestry.
Increased Native American ancestry has been linked to increased risk of relapse among Hispanic children with ALL, 6 but no study has yet investigated the contribution of genome-wide Native American ancestry to ALL incidence. Using genome-wide SNP data from 298 Hispanic children with B cell ALL and 456 matched controls from the California Childhood Leukemia Study (CCLS), we investigated whether genome-wide NativeAmerican ancestry was associated with increased risk of B-cell ALL. Additionally, we assessed whether the risk alleles at loci identified in genome-wide association studies of European-ancestry populations (IKZF1, CDKN2A, PIP4K2A, ARID5B, CEBPE) were more common in individuals with greater levels of Native American ancestry. Finally, we quantified the contribution of these validated risk loci to the increased ALL incidence observed in Hispanics relative to populations of European or African ancestry.
Study participants were Hispanic children from the CCLS, whose recruitment and enrollment procedures have been described in detail previously (Supplementary Table S1 ). 7, 8 Cytogenetic characteristics of included cases are shown in Supplementary  Table S1 . DNA was isolated from dried bloodspots collected at birth and archived by the California Department of Public Health. Samples were genotyped using the Illumina OmniExpress platform, assaying 730 525 single-nucleotide polymorphism (SNPs). Samples with genotyping call rateso98%, with discordant sex information (reported versus genotyped sex), or showing evidence of cryptic relatedness were excluded from analyses. To exclude poorly genotyped SNPs, SNPs with genotyping call rates o98% or Hardy-Weinberg Equilibrium P-value o1 Â 10 À 5 in controls were removed from analyses.
A linkage-reduced set of 63 303 autosomal SNPs, evenly distributed across the genome, was extracted from the Accepted article preview online 25 April 2013; advance online publication, 17 May 2013
